Boston Scientific net down as heart device sales slow
CHICAGO (Reuters) - Boston Scientific Corp., which expects shortly to complete its acquisition of Guidant Corp., said on Tuesday that quarterly earnings fell 7.3 percent on slower sales of devices used to treat clogged heart arteries.
But the maker of drug-coated stents -- the small wire mesh devices inserted into coronary arteries to keep blood flowing -- said sales beat Wall Street expectations, and the company's shares rose nearly 2 percent
· Read The Full Boston Scientific Taxus Stent Article From Reuters -->
·
Read All Boston Scientific Taxus Stent News Stories -->